ADDISON, Texas, Nov. 28, 2016 /PRNewswire/ -- Solis Mammography's Chief Medical Officer and President of Rose Imaging Physicians Group, Dr. Stephen Rose, presented his abstract on Tomosynthesis Impact on Screening Patients 40 to 49 on Sunday, Nov. 27, at the Radiological Society of North America 2016 Scientific Assembly and Annual Meeting in Chicago. Dr. Rose discovered that recall rates, cancer detection and invasive cancer detection for women under the age of 50 were significantly improved with the addition of tomosynthesis (3-D) to mammography.
Background: In January, the U.S. Preventive Services Task Force changed its recommendations, advising women to start their mammograms at age 50. In October 2015, after 30 years, the American Cancer Society changed its guidelines in Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update advising women to begin screening by age 45 and then biennial (every 2 years) after age 55. One of the major concerns both reports cited was false positives (also known as recall rates).
The men and women who participated in these organizations' changes were not peer-reviewed radiologists, used 2-D mammography research and did not consider the benefits of tomosynthesis (3-D mammography).
According to the American Cancer Society's Breast Cancer Facts & Figures report, in 2015 231,840 women were diagnosed with invasive breast cancer and 46,350 were under the age of 50 when diagnosed.
Additionally, younger women (under the age of 50) are more likely to have dense breast tissue, increasing the possibility of a false negative (not detecting an existing asymptomatic breast cancer). Breast density makes it more difficult for radiologists to see abnormal growths using digital mammography (2-D).
Study: Dr. Rose and Solis Mammography collected data from Jan. 1-Dec. 31, 2015, from a network of community-based screening centers (geography includes N.C., Ohio, Texas and Ariz.) of women from 40-49 years old to investigate if the addition of tomosynthesis (3-D) to mammography could improve screening performance outcomes for women under the age of 50. The study covered 65,457 screening exams, and 45,320 digital mammography (2-D) exams and 20,137 tomosynthesis (3-D) exams were performed. (Tomosynthesis patients incurred an additional out-of-pocket fee for the test.) The Chi square test was performed.
Results: Tomosynthesis Impact on Screening Patients Age 40-49 results:
|
Women >50 Years Old |
Digital Mammography (2-D) |
Tomosynthesis (3-D) |
Difference |
Probability (p) |
|
Recall Rates per 1000 |
115 |
108 |
7 |
p=0.013 |
|
Total cancer Detection Rates |
2.1 |
3.1 |
1.0 |
p=0.021 |
|
Invasive Cancer Detection Rates |
1.2 |
1.8 |
0.8 |
p=0.014 |
Improvement of recall rates and cancer detection rates increases with breast density:
|
Women >50 Years Old |
Digital Mammography (2-D) Cancer Detection |
Tomosynthesis (3-D) Cancer Detection |
Digital Mammography (2-D) Recall Rates |
Tomosynthesis (3-D) Recall Rates |
|
Fatty |
0 |
1 |
5 |
6 |
|
Scattered Fibroglandular |
2 |
3 |
9 |
8 |
|
Heterogeneously Dense |
3 |
4 |
14 |
13 |
|
Extremely Dense |
0 |
4 |
11 |
12 |
The addition of tomosynthesis (3-D) in women under 50 years old were:
Conclusion: The addition of tomosynthesis (3-D) to mammography in women 40 to 49 years old shows improved outcomes in recall rates and cancer detection rates (similar to the general population).
Tomosynthesis (3-D) addresses a primary concern regarding screening women in their 40s by reducing recall rates as cited in both the USPSTF and the ACS guideline changes.
Adding tomosynthesis (3-D) to mammography takes about the same amount of time as digital mammography yet takes around 60 pictures. Radiologists can now see cancers as early as stage zero with tomosynthesis.
"Our study is confirming the benefits of tomosynthesis. For a disease with no known form of prevention, early detection is key and the earliest detection is with tomosynthesis, especially in women under 50 years old with dense beast tissue," commented Dr. Rose.
"For years, radiologists and referring physicians have attested to the importance of early detection in saving lives and in offering women the best treatment options," said James Polfreman, president and CEO, Solis Mammography. "Adding tomosynthesis to mammography represents the best technology available, offering more and clearer images of breast tissue, and less recalls, which in turn means less anxiety for the women we serve. Medicare began coverage for 3-D mammography in January 2015 and Cigna recently announced that it is now including 3-D mammography in their national coverage plans. This is an important milestone for women's health, and we hope that with research like Dr. Rose's, more private insurers will follow suit."
Dr. Rose joined Solis Mammography as its chief medical officer in April of 2014. He is responsible for clinical quality, clinical research and leadership of Solis' breast radiologists; serves as a spokesperson for the company regarding clinical quality; and plays a key role in the strategic growth of the company.
Dr. Rose is also the founder and president of Rose Imaging Specialists, P.A., the nation's largest group of breast imaging specialists. He is a graduate of the Johns Hopkins University School of Medicine in Baltimore, Maryland. His residency in Diagnostic Radiology was completed at the University of Texas at Houston, including training at M.D. Anderson, Texas Children's Hospital Memorial Hermann Health System and St. Joseph's Hospital of Houston. He is a board-certified, nationally renowned breast radiologist and has dedicated his practice to the diagnosis of early breast cancer for almost two decades. Today he is considered one of the nation's leading experts regarding tomosynthesis.
To download a copy of Dr. Rose's abstract Tomosynthesis Impact on Screening Patients 40 to 491 go to: http://archive.rsna.org/2016/16015111.html.
About Solis Mammography
Celebrating 30 years in breast imaging, Solis Mammography is a specialized healthcare provider focused on delivering women an exceptional mammography experience. Headquartered in Addison, Texas, Solis currently operates 41 centers across six major markets – North Texas; Houston, Texas; Phoenix, Arizona; Columbus, Ohio; Greensboro, North Carolina, and through its recent acquisition of Washington Radiology Associates (WRA), the D.C. metropolitan area. The company operates both wholly-owned centers and multiple successful joint ventures with hospital partners. Solis Mammography (including WRA), serves more than 600,000 patients each year with highly-specialized imaging services including screening and diagnostic mammography (2-D and 3-D), computer-aided detection, breast ultrasound, stereotactic biopsy and ultrasound-guided biopsy. For more information, visit www.SolisMammo.com, like on Facebook, follow on Pinterest, and subscribe to the YouTube channel.
1Abstract citation: Rose,S, Tomosynthesis Impact on Screening Patients 40 to 49. Radiological Society of North America 2016 Scientific Assembly and Annual Meeting, November 27 - December 2, 2016, Chicago IL. archive.rsna.org/2016/16015111.html Accessed November 23, 2016)
For more information, contact Jo Trizila, TrizCom PR, 972-247-1369 or jo@trizcom.com.